Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis
Open Access
- 1 November 2003
- journal article
- research article
- Published by Elsevier in The American Journal of Pathology
- Vol. 163 (5), 2021-2031
- https://doi.org/10.1016/s0002-9440(10)63560-2
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic indexBlood, 2003
- Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastasesJournal of Clinical Pathology, 2002
- Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cellsBlood, 2002
- Osteoprotegerin differentially regulates protease expression in osteoclast culturesBiochemical and Biophysical Research Communications, 2002
- Immunohistochemical study of receptor activator of nuclear factor kappa‐B ligand (RANK‐L) in human osteolytic bone tumorsJournal of Surgical Oncology, 2002
- RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of BoneAmerican Journal of Clinical Pathology, 2002
- Osteolysis and cancerJCI Insight, 2001
- Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast FormationBiochemical and Biophysical Research Communications, 2000
- Interactions between Cancer and Bone Marrow Cells Induce Osteoclast Differentiation Factor Expression and Osteoclast-like Cell Formation in VitroBiochemical and Biophysical Research Communications, 2000
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998